Recombinant Human CRELD2 Protein

重组人CRELD2蛋白 | 重组人富含半胱氨酸的EGF样结构域蛋白2

CRELD2 | cysteine-rich with EGF-like domain protein 2 | cysteine-rich with EGF-like domains 2 | DKFZp667O055 | MGC11256

rp188300-10μg

10μg

无动物源

≥90%(SDS-PAGE)

Cysteine-rich with EGF-like domain protein 2 (CRELD2) is an approximately 60 kDa glycoprotein that contains two EGF‑like domains and two FU domains. Mature human CRELD2 shares approximately 78% aa sequence identity with mouse and rat CRELD2. Alternative splicing of human CRELD2 generates additional isoforms with substitutions, deletions, and/or insertions in the C-terminal half of the molecule. The various isoforms are widely expressed in fetal and adult tissues. CRELD2 localizes to the endoplasmic reticulum and Golgi and can also be secreted. It is up‑regulated during the cellular stress‑induced unfolded protein response (UPR), cartilage and bone pathologies (MED and MCDS), and arsenic‑induced liver toxicity. CRELD2 interacts intracellularly with the alpha 4 and beta 2 subunits of the nicotinic acetylcholine receptor and inhibits cell surface expression of the receptor. CRELD2 expression is up‑regulated in prostate cancer by dihydroxytestosterone and is down‑regulated following anti-androgen treatment.

Measured by its ability to induce adhesion of ATDC5 mouse chondrogenic cells. The ED50 for this effect is 1.0-5.0 μg/mL.

重组表达

36.3 kDa

C-His

42.9-50.7 kDa, under reducing conditions

HEK293 Accession #: Q6UXH1 | HEK293

<1.0 EU/μg

人(Human)

1-353 aa (S295A, E325G)

MRLPRRAALGLLPLLLLLPPAPEAAKKPTPCHRCRGLVDKFNQGMVDTAKKNFGGGNTAWEEKTLSKYESSEIRLLEILEGLCESSDFECNQMLEAQEEHLEAWWLQLKSEYPDLFEWFCVKTLKVCCSPGTYGPDCLACQGGSQRPCSGNGHCSGDGSRQGDGSCRCHMGYQGPLCTDCMDGYFSSLRNETHSICTACDESCKTCSGLTNRDCGECEVGWVLDEGACVDVDECAAEPPPCSAAQFCKNANGSYTCEECDSSCVGCTGEGPGNCKECISGYAREHGQCADVDECALAEKTCVRKNENCYNTPGSYVCVCPDGFEGTEDACVPPAEAEATEGESPTQLPSREDLHHHHHH

Yes

Yes